Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypoplastic Left Heart Syndrome: early-phase trial registry
1 of 4 indexed Hypoplastic Left Heart Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hypoplastic Left Heart Syndrome: 4 US clinical trials tracked, 1 recruiting.
Hypoplastic Left Heart Syndrome is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Longeveron, running 1 of these trials.
Enrollment posture brief
Registry condition hypoplastic-left-heart-syndrome
OPEN 1 | RECR 25% | LATE 0 | EARLY 2 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Hypoplastic Left Heart Syndrome lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypoplastic Left Heart Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypoplastic Left Heart Syndrome is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Effect of Fetal Aortic Valvuloplasty on Outcomes
Queen Silvia Children's Hospital, Gothenburg, Sweden
NCT05386173
Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome
Timothy J Nelson, MD, PhD
NCT03779711
Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.
Longeveron
NCT04925024
Single Ventricle Outcome
Emory University
NCT00308217
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypoplastic Left Heart Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypoplastic Left Heart Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypoplastic Left Heart Syndrome page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Hypoplastic Left Heart Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Longeveron sponsors the most Hypoplastic Left Heart Syndrome trials on record, review their full trial history before evaluating a specific study. See Longeveron's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypoplastic Left Heart Syndrome condition card totals 4 registered trials; most-linked intervention Lomecel-B medicinal signaling cells; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.